144 related articles for article (PubMed ID: 8867870)
21. Modulation of delta opioid agonist-induced antinociception by repeated morphine pretreatment in rhesus monkeys.
Negus SS; Banks ML; Folk JE; Rice KC
Life Sci; 2010 Mar; 86(11-12):385-92. PubMed ID: 20096291
[TBL] [Abstract][Full Text] [Related]
22. Repeated acquisition of behavioral chains in squirrel monkeys: comparisons of a mu, kappa and delta opioid agonist.
Pakarinen ED; Woods JH; Moerschbaecher JM
J Pharmacol Exp Ther; 1995 Feb; 272(2):552-9. PubMed ID: 7853168
[TBL] [Abstract][Full Text] [Related]
23. Clocinnamox antagonism of the antinociceptive effects of mu opioids in squirrel monkeys.
Pitts RC; Allen RM; Walker EA; Dykstra LA
J Pharmacol Exp Ther; 1998 Jun; 285(3):1197-206. PubMed ID: 9618423
[TBL] [Abstract][Full Text] [Related]
24. Magnitude of tolerance to fentanyl is independent of mu-opioid receptor density.
Chan KW; Duttory A; Yoburn BC
Eur J Pharmacol; 1997 Jan; 319(2-3):225-8. PubMed ID: 9042594
[TBL] [Abstract][Full Text] [Related]
25. In vivo apparent pA2 analysis in rats treated with either clocinnamox or morphine.
Walker EA; Richardson TM; Young AM
Psychopharmacology (Berl); 1996 May; 125(2):113-9. PubMed ID: 8783384
[TBL] [Abstract][Full Text] [Related]
26. Effects of heroin and its metabolites on schedule-controlled responding and thermal nociception in rhesus monkeys: sensitivity to antagonism by quadazocine, naltrindole and beta-funaltrexamine.
Negus SS; Brandt MR; Gatch MB; Mello NK
Drug Alcohol Depend; 2003 May; 70(1):17-27. PubMed ID: 12681522
[TBL] [Abstract][Full Text] [Related]
27. Behavioral effects of the systemically active delta opioid agonist BW373U86 in rhesus monkeys.
Negus SS; Butelman ER; Chang KJ; DeCosta B; Winger G; Woods JH
J Pharmacol Exp Ther; 1994 Sep; 270(3):1025-34. PubMed ID: 7932149
[TBL] [Abstract][Full Text] [Related]
28. Effects of mu-opioid agonists on cocaine- and food-maintained responding and cocaine discrimination in rhesus monkeys: role of mu-agonist efficacy.
Negus SS; Mello NK
J Pharmacol Exp Ther; 2002 Mar; 300(3):1111-21. PubMed ID: 11861822
[TBL] [Abstract][Full Text] [Related]
29. Discriminative stimulus effects of the mixed-opioid agonist/antagonist dezocine: cross-substitution by mu and delta opioid agonists.
Picker MJ
J Pharmacol Exp Ther; 1997 Dec; 283(3):1009-17. PubMed ID: 9399970
[TBL] [Abstract][Full Text] [Related]
30. 3-Alkyl ethers of clocinnamox: delayed long-term mu-antagonists with variable mu efficacy.
Husbands SM; Sadd J; Broadbear JH; Woods JH; Martin J; Traynor JR; Aceto MD; Bowman ER; Harris LS; Lewis JW
J Med Chem; 1998 Aug; 41(18):3493-8. PubMed ID: 9719602
[TBL] [Abstract][Full Text] [Related]
31. Irreversible opioid antagonist effects of clocinnamox on opioid analgesia and mu receptor binding in mice.
Burke TF; Woods JH; Lewis JW; Medzihradsky F
J Pharmacol Exp Ther; 1994 Nov; 271(2):715-21. PubMed ID: 7965787
[TBL] [Abstract][Full Text] [Related]
32. Selective enhancement of fentanyl-induced antinociception by the delta agonist SNC162 but not by ketamine in rhesus monkeys: Further evidence supportive of delta agonists as candidate adjuncts to mu opioid analgesics.
Banks ML; Folk JE; Rice KC; Negus SS
Pharmacol Biochem Behav; 2010 Dec; 97(2):205-12. PubMed ID: 20678514
[TBL] [Abstract][Full Text] [Related]
33. Buprenorphine and methoclocinnamox: agonist and antagonist effects on respiratory function in rhesus monkeys.
Kishioka S; Paronis CA; Lewis JW; Woods JH
Eur J Pharmacol; 2000 Mar; 391(3):289-97. PubMed ID: 10729371
[TBL] [Abstract][Full Text] [Related]
34. Oral ethanol-reinforced responding in rhesus monkeys: effects of opioid antagonists selective for the mu-, kappa-, or delta-receptor.
Williams KL; Woods JH
Alcohol Clin Exp Res; 1998 Nov; 22(8):1634-9. PubMed ID: 9835275
[TBL] [Abstract][Full Text] [Related]
35. Micro/kappa opioid interactions in rhesus monkeys: implications for analgesia and abuse liability.
Negus SS; Schrode K; Stevenson GW
Exp Clin Psychopharmacol; 2008 Oct; 16(5):386-99. PubMed ID: 18837635
[TBL] [Abstract][Full Text] [Related]
36. Central antinociception induced by ketamine is mediated by endogenous opioids and μ- and δ-opioid receptors.
Pacheco Dda F; Romero TR; Duarte ID
Brain Res; 2014 May; 1562():69-75. PubMed ID: 24675031
[TBL] [Abstract][Full Text] [Related]
37. Discriminative stimulus effects of the nonpeptidic delta-opioid agonist SNC80 in rhesus monkeys.
Brandt MR; Negus SS; Mello NK; Furness MS; Zhang X; Rice KC
J Pharmacol Exp Ther; 1999 Sep; 290(3):1157-64. PubMed ID: 10454490
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of morphine-like effects of the mixed mu/delta agonist morphine-6-
Yadlapalli JSK; Bommagani SB; Mahelona RD; Wan A; Gannon BM; Penthala NR; Dobretsov M; Crooks PA; Fantegrossi WE
Pharmacol Res Perspect; 2018 Jul; 6(4):e00403. PubMed ID: 29930811
[TBL] [Abstract][Full Text] [Related]
39. Use of irreversible antagonists to determine the relative efficacy of mu-opioids in a pigeon drug discrimination procedure: comparison of beta-funaltrexamine and clocinnamox.
Barrett AC; Smith ES; Picker MJ
J Pharmacol Exp Ther; 2003 Jun; 305(3):1061-70. PubMed ID: 12649297
[TBL] [Abstract][Full Text] [Related]
40. Clocinnamox: a novel, systemically-active, irreversible opioid antagonist.
Comer SD; Burke TF; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1992 Sep; 262(3):1051-6. PubMed ID: 1326622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
